ClinicalTrials.gg
Not yet recruitingNCT06785974SPIRALUpdated Jan 22, 2025

Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis

A Phase 4 interventional study of Atorvastatin and Placebo in Atherosclerosis, Melanoma and Immune-related Adverse Event, sponsored by Erasmus Medical Center. Not yet recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by Erasmus Medical Center · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies testing atorvastatin in Atherosclerosis — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Atherosclerosis.

Planned enrollment
7th of 24
140 · median 52
Started
2025
the only one that year
Phase 4
10 of 24
1 open now
Registered
24th of 24
by date
Lead sponsor
1 of 24
Erasmus Medical Center

Among the 24 studies testing atorvastatin in Atherosclerosis, this one is the 7th largest by planned enrollment, is the only one that started in 2025, is one of 10 in phase 4, and was the 24th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

1 of the 24 studies testing atorvastatin in Atherosclerosis is open now, in 1 country.

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing atorvastatin in Atherosclerosis, or all of them as a file.
02

Study summary

The goal of this interventional study is to test whether atorvastatin prevents accelerated progression of atherosclerosis in melanoma patients who receive immune checkpoint inhibitor (ICI) therapy. The main questions it aims to answer are:

  • difference in percentage growth of total atherosclerotic plaque volume (+ calcified and non-calcified plaque volume) in the descending thoracic segment of the aorta
  • difference in percentage growth of total atherosclerotic plaque volume (+ calcified and non-calcified plaque volume) in coronary arteries.

Researchers will compare patients that receive ICI-therapy and atorvastatin with patients that receive ICI-therapy + placebo to see if atorvastatin will prevent accelerated ICI induced plaque growth.

Read the detailed description

Rationale: Immune checkpoint inhibitors (ICIs) are often highly effective anti-cancer therapies but predispose patients receiving this treatment to cardiovascular disease and thrombotic events. One of the mechanisms by which ICIs increase cardiovascular risk is by stimulation of inflammation and atherosclerosis. Statins (e.g., atorvastatin) are frequently prescribed and effective anti-atherogenic agents, which could provide protective effects on the cardiovascular system in this patient population whilst and after receiving ICI, minimizing cardiovascular sequelae.

The objective of this study is to study if addition of atorvastatin prevents accelerated progression of atherosclerosis during ICI therapy. In addition, the investigators would like to study the effects of atorvastatin during ICI therapy on endothelial function, epicardial fat volume, and hemostatic and inflammatory parameters.

The main study endpoint is the difference in percentage growth of total atherosclerotic plaque volume in the descending thoracic segment of the aorta between intervention and control group, expressed in indexed percentage growth /year.

Secondary endpoints are differences in non-calcified and calcified plaque volume in the thoracic arteries and coronary arteries, epicardial fat volume, endothelial function, and quality of life. Exploratory endpoints include effect on hemostatic and inflammation markers, lipid levels, progression free survival, event free survival, and overall survival.

Trial design Placebo controlled prospective randomised controlled trial.

Trial population Melanoma patients who are scheduled to receive ICI therapy (nivolumab, pembrolizumab, or a combination of anti-PD1/ipilimumab; (neo)adjuvant, irresectable or metastasized melanoma) according to standard-of-care who are also eligible to initiate statin therapy.

The intervention group receives atorvastatin 20mg daily together with ICI therapy. The control group receives placebo together with ICI therapy.

Both groups will undergo two coronary and thoracic CT-scans. In addition, blood withdrawal will take place fourthly during the study. Furthermore, endothelial function will be assessed by means of the EndoPAT device at baseline and after one year of follow-up.

Ethical considerations relating to the clinical trial including the expected benefit to the individual subject or group of patients represented by the trial subjects as well as the nature and extent of burden and risks: Patients in the intervention group will receive atorvastatin, of which safety and tolerability will be carefully monitored. Coronary atherosclerosis will be assessed via two coronary CT-scans, yielding a total limited extra radiation exposure of 4-10mSv. Blood withdrawal will be combined with regular blood withdrawal time points for standard care or will be withdrawn from the intravenous catheter for ICI administration. Vascular endothelial dysfunction will be assessed via Endothelial Peripheral Arterial Tonometry (EndoPAT) by recording finger arterial pulsatile volume change. This non-invasive method forms a minimal extra burden for participating patients. The investigators hypothesize that atorvastatin prevents accelerated progression of atherosclerosis and ameliorates ICI-induced vascular endothelial dysfunction.

03

Conditions studied

  • Atherosclerosis
  • Melanoma
  • Immune-related Adverse Event

Keywords

  • Statin
  • Immune Checkpoint Inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • Age ≥ 18 years
  • Able to understand the written information and able to give
  • Melanoma diagnosis with planned ICI treatment according to standard of care (nivolumab, pembrolizumab, monotherapy or combination therapy with ipilimumab)
  • Presence of atherosclerosis in the descending thoracic aorta at baseline.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation
  • Baseline statin use or previously reported statin intolerance
  • Current or recent (≤1 year) history of alcohol or drug abuse
  • for statin therapy, including:

    • Active liver disease, including /AST levels ≥ 3x
    • (History of) myopathy Congenital muscular disorder History of (drug-induced) rhabdomyolysis History of drug-induced myopathy with elevated creatine kinase (CK)
    • Severe kidney failure ( \< 30 ml/min)
  • Use of essential medication with (potential) interactions with atorvastatin, including:

    • strong inhibitors such as clarithromycin, ciclosporin, itraconazol, ketoconazole, voriconazol, posconazol, agents, protease inhibitors
    • BCRP inhibitors such as elbasvir and grazoprevir
    • Fibrates (including gemfibrozil)
  • \< 12 months
  • High MESA-score at baseline
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Intervention/ Atorvastatin arm

    Patient will receive 20mg of atorvastatin daily together with ICI-therapy

    Drug: Atorvastatin

  • Placebo comparator
    Placebo arm

    Patient will receive placebo daily together with ICI-therapy

    Drug: Placebo

Interventions

  • Daily 20mg atorvastatin.

    Also known as: Lipitor, Atorvastatin Mylan

  • DrugPlacebo

    Daily Placebo in combination with ICI-therapy

06

What researchers measure

Primary outcomes

  1. Percentual annual growth of atherosclerotic plaques in the descending thoracic aorta

    The percentage difference in atherosclerotic plaque volume in the descending part of the thoracic after 1 year of ICI-therapy will be compared to the atherosclerotic plaque volume at baseline.

    Time frame: 1 year

Secondary outcomes

  1. Difference in percentage increase in non-calcified and calcified atherosclerotic plaque volume in the descending thoracic aorta

    Difference in percentage increase in non-calcified and calcified atherosclerotic plaque volume in the descending thoracic aorta 1 year after the start of ICI therapy in the intervention versus the control group

    Time frame: 1 year

  2. Difference in percentage increase in total, non-calcified and calcified coronary artery atherosclerotic plaque volume

    Difference in percentage increase in total, non-calcified and calcified coronary artery atherosclerotic plaque volume

    Time frame: 1 year

  3. Difference in increase in coronary calcification score (Agatston score) and Multi-Ethnic Study of Atherosclerosis (MESA) score

    Difference in increase in coronary calcification score (Agatston score) and MESA score. MESA score calculates the 10-year risk in percentage of developing coronary heart disease.

    Time frame: 1 year

  4. Difference in change in epicardial fat volume

    Difference in change in epicardial fat volume

    Time frame: 1 year

  5. Difference in reactive hyperaemia in-dex

    Difference in reactive hyperaemia in-dex as a marker of endothelial dysfunc-tion using peripheral arterial tonometry (EndoPAT) between intervention and control group.

    Time frame: 1 year

  6. Difference in Quality of Life between intervention and control group using the FACT-M and EQ5D5L questionnaire.

    Difference in QoL between intervention and control group using the FACT-M and the EQ5D5L questionnaires

    Time frame: Baseline, 3 months, 6 months and 1 year after the start of ICI therapy

  7. Differences in the number of adverse events

    Differences in the number of adverse events between intervention and control group during the first year after start of ICI therapy, graded according to CTCAE criteria, version 5.0.

    Time frame: 1 year

Other outcomes

  1. The effect of atorvastatin on median Progression Free Survival in months

    The median progression free survival (PFS) in patients with advanced melanoma will be obtained after one and three years and will be calculated in months. Progression Free Survival (PFS) is defined as duration from randomization until disease progression.

    Time frame: 1 and 3 years

  2. The effect of statins on the median Overall Survival in months

    The effect of statins on the median overall survival in months in patients with advanced disease after 1 and after 3 years. Overall Survival (OS) is defined as the duration from randomization until death from any cause

    Time frame: 1 and 3 years

  3. The effect of statins on the median Event Free Survival in months

    The effect of statins on the median Event Free Survival in months in patients with advanced disease after 1 and after 3 years. Event Free Survival (EFS) is defined as the time from the start of the study treatment to the occurrence of progression to unresectable melanoma before surgery (in the neoadjuvant setting), disease recurrence, or death due to melanoma or due to treatment, whichever occurs first.

    Time frame: 1 and 3 years

  4. Difference in various concentration levels of hemostatic biomarkers

    Difference in change in concentration levels of various markers of the hemostatic system activation (including d-dimer, fibrinogen, factor VIII, von Willebrand factor) between the intervention and control group at 3 months, 6 months, and 1 year after the start of ICIs.

    Time frame: Baseline, 3 months, 6 months and 1 year after the start of ICI therapy

  5. Difference in serum concentration of cardiovascular risk profile biomarkers

    Difference in serum levels of the following parameters: HsCRP, VCAM, ICAM, TNF-α, IL-1β, IL-6, IL-10, Lipid profile, lp(a) between the intervention and control group at 3 months, 6 months and 1 year after the start of ICIs.

    Time frame: Baseline, 3 months, 6 months and 1 year after the start of ICI therapy

07

Study locations

1 site
  • Erasmus Universitair Medisch Cetrum Rotterdam
    Rotterdam, Zuid Holland 3015GD, Netherlands
08

References and documents

Individual participant data

Plan to share: Yes — The data will only become available after the study has been completed for at least 1 year. Only the IPD that have given informed consent to use the anonymous data will be available. After completion of the study, the Erasmus MC policy for requesting data will be applied. Furthermore, the General Data Protection Regulation must be complied with at all times.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: 2 years inclusion, 1 year after completion, 1 year analysis approximately 01-08-2028. Data will be available for 15 years after date of obtaining.

Access criteria: The data will only become available after the study has been completed for at least 1 year. After completion of the study, the Erasmus MC policy for requesting data will be applied. Furthermore, the General Data Protection Regulation must be complied with at all times.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Feb 2027, 24 months later.

Of 45 non-industry phase 4 interventional studies under Atherosclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 24 months is below that.

Counting every sponsor, half of 55 studies reached it within 30 months; a quarter within 17 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2024
First posted
Jan 22, 2025
StartEst.
Feb 2025
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2030
Last update
Jan 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06785974
Collaborators
Amphia Hospital
Responsible party
Jorie Versmissen (Principal Investigator, Erasmus Medical Center) — Principal investigator
First posted
Jan 22, 2025
Start date
Feb 2025 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Feb 2030 (estimated)
Last update
Jan 22, 2025

Study contacts

Tom Uyl, MD
Contact
t.uyl@erasmusmc.nl
010-7033202
Jorie Versmissen, MD, PhD
Contact
j.versmissen@erasmusmc.nl
010-7033202
Jorie Versmissen, MD,PhD
principal investigator · Department Internal Medicine, Hospital Pharmacy, Erasmus MC Rotterdam

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion